Why the study?
Anticancer drug delivery to tumor tissue is hindered by toxicity and poor aqueous solubility, leading to interest in high-density lipoproteins as drug delivery vehicles.
HDLs represent a promising biocompatible vehicle for targeted delivery of chemotherapeutic drugs to tumor tissues, potentially overcoming current limitations of toxicity and poor solubility.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for HDL-based chemotherapeutic delivery; leaves open clinical translation and safety trials.
High-density lipoproteins (HDLs) are the smallest lipoprotein with the highest level of protein in their surface. The main role of HDLs are reverse transport of cholesterol from peripheral tissues to the liver. More recently, HDLs have been considered as a new drug delivery system because of their small size, proper surface properties, long circulation time, biocompatibility, biodegradability, and low immune stimulation. Delivery of anticancer drug to the tumor tissue is a major obstacle against successful chemotherapy, which is because of the toxicity and poor aqueous solubility of these drugs. Loading chemotherapeutic drugs in the lipid core of HDLs can overcome the aforementioned problems and increase the efficiency of drug delivery. In this review, we discuss the use of HDLs particles in drug delivery to the tumor tissue and explain some barriers and limitations that exist in the use of HDLs as an ideal delivery vehicle.
No takes yet. Share an insight, caveat, or question.
Sarhadi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: